On January 23, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data showcasing the benefits of Guardant’s precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025 (Press release, Guardant Health, JAN 23, 2025, View Source [SID1234649860]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key focus areas in Guardant’s co-authored abstracts and collaborator presentations utilizing Guardant products include the impact of mutations on treatment response in colorectal cancer and biliary tract cancers, and additional support for the benefits of blood-based screening in colorectal, gastric and esophageal cancers. A rapid oral presentation will feature data from the phase II NEO trial highlighting Guardant Reveal as a decision tool to support organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision and observation.
"Data increasingly supports the value of precision oncology tools, and specifically liquid biopsy, in detecting GI cancers, informing treatment selection, and monitoring for recurrence and therapy response," said Craig Eagle, MD, Guardant Health chief medical officer. "Findings presented at ASCO (Free ASCO Whitepaper) GI demonstrate the advancements being made by Guardant Health and our partners in these areas and show the potential for these tools to provide even more personalized cancer care, leading to better patient outcomes."
Guardant Health ASCO (Free ASCO Whitepaper) GI 2025 Co-Authored Posters and Presentations
Time and Location
Title
Abstract and
Presentation Type
Guardant Reveal
January 25, 2025
9:15 – 10:00 am PST
Level 2, Ballroom
Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28)
Rapid Oral Abstract
Session C
Abstract #20
Guardant360
January 25, 2025
7:00 – 7:55 am PST
Level 1, West Hall
Retrospective study evaluating the genomic landscape of anal squamous cell carcinoma using liquid biopsy
Poster Session C
Abstract #8
Landscape of metastatic colorectal cancer (CRC) using comprehensive circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in India: Expanding beyond RAS and RAF
Poster Session C
Abstract #49
GuardantINFORM
January 24, 2025
11:30 am – 1:00 pm PST
Level 1, West Hall
Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy
Poster Session B
Abstract #548
ShieldTM
January 25, 2025
7:00 – 7:55 am PST
Level 1, West Hall
Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence
Poster Session C
Abstract #93
A method for classifying colorectal cancer and gastric/esophageal cancer using blood-based testing
Poster Session C
Abstract #52
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO (Free ASCO Whitepaper) GI 2025 can be found on the ASCO (Free ASCO Whitepaper) website.